Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Cardiometabolic Screening Program

NCT05386719 · View on ClinicalTrials.gov ↗

Study Summary

This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional resources for management.

Interventions

  • OTHER Prescreening
  • OTHER Screening and Enrollment
  • BEHAVIORAL Baseline
  • BEHAVIORAL Interpret BMI
  • OTHER Interpret HbA1c

Study Locations (1)

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2022-06-03
Est. Completion 2027-06-01
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05386719

The ClinicalTrials.gov registry entry for NCT05386719 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 311 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions — of which Prescreening is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05386719 reports 1 study location spanning 1 distinct geographic area — top geographies include Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05386719 about?

NCT05386719 is a clinical study titled "Cardiometabolic Screening Program". This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional r...

What is the current status of trial NCT05386719?

This trial is currently recruiting. It is a NA study. The enrollment target is 450 participants. The study started on 2022-06-03. Estimated completion is 2027-06-01.

What conditions does trial NCT05386719 study?

This clinical trial studies the following conditions: Breast Cancer, Early-stage Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05386719?

The interventions under investigation include: Prescreening (OTHER), Screening and Enrollment (OTHER), Baseline (BEHAVIORAL), Interpret BMI (BEHAVIORAL), Interpret HbA1c (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05386719?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 311 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05386719 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial